drugset / Trial / NCT03396484
Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes
RandomizedCrossoverDouble-blindPrevention
Summary
A study is to see if methyldopa can change the immune system's attack on insulin producing cells in people at early stages of type 1 diabetes.
Timeline
- Start
- 2020-09
- Primary completion
- 2022-03
- Completion
- 2022-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methyldopa | Unknown | 500 mg | Oral |